{"id":"thymosin-alpha1-pegylated-interferon-alpha2a","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"20-40","effect":"Headache"},{"rate":"10-30","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"5-15","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL412531","moleculeType":"Protein","molecularWeight":"3051.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Thymosin alpha1 is an immunomodulatory peptide that promotes T-cell development and activation, particularly enhancing CD4+ and CD8+ T-cell function. Pegylated interferon-alpha2a is a type I interferon with extended half-life that activates natural killer cells, macrophages, and promotes antiviral/anti-tumor gene expression. Together, they provide synergistic immune stimulation for treating chronic viral infections and certain malignancies.","oneSentence":"This combination enhances immune response by stimulating T-cell maturation and proliferation (thymosin alpha1) while amplifying interferon-mediated antiviral and anti-tumor effects (pegylated interferon-alpha2a).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:33.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B (marketed combination therapy)"},{"name":"Chronic hepatitis C (marketed combination therapy)"}]},"trialDetails":[{"nctId":"NCT02646189","phase":"PHASE1, PHASE2","title":"Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2011-08","conditions":"Hepatitis B, Chronic","enrollment":12},{"nctId":"NCT00291616","phase":"PHASE4","title":"Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2005-12","conditions":"Chronic Hepatitis B","enrollment":52},{"nctId":"NCT01178996","phase":"PHASE3","title":"Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":552},{"nctId":"NCT00040027","phase":"PHASE3","title":"Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin","status":"COMPLETED","sponsor":"SciClone Pharmaceuticals","startDate":"2002-04","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":500},{"nctId":"NCT00039962","phase":"PHASE3","title":"Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin","status":"COMPLETED","sponsor":"SciClone Pharmaceuticals","startDate":"2002-05","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Thymosin alpha1 & Pegylated Interferon-alpha2a","genericName":"Thymosin alpha1 & Pegylated Interferon-alpha2a","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination enhances immune response by stimulating T-cell maturation and proliferation (thymosin alpha1) while amplifying interferon-mediated antiviral and anti-tumor effects (pegylated interferon-alpha2a). Used for Chronic hepatitis B (marketed combination therapy), Chronic hepatitis C (marketed combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}